DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
AIN457 is an investigational drug.
There have been 47 clinical trials for AIN457. The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2018.
The most common disease conditions in clinical trials are Psoriasis, Arthritis, and Arthritis, Psoriatic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), and Novartis.
There are two US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for AIN457
|An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)||Novartis Pharmaceuticals||Phase 3|
|A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis||Novartis Pharmaceuticals||Phase 2|
|Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis||Novartis Pharmaceuticals||Phase 4|
Top disease conditions for AIN457
Top clinical trial sponsors for AIN457
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AIN457||Start Trial||Substituted pyrimidinone-phenyl-pyrimidinyl compounds||CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)||Start Trial|
|AIN457||Start Trial||Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients||Corning Incorporated (Corning, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AIN457||World Intellectual Property Organization (WIPO)||2013086208||2031-12-06||Start Trial|
|AIN457||European Patent Office||2796429||2033-04-24||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|